Pairing analysis of clinical prognosis between liver transplantation with autoimmune liver disease and viral hepatitis cirrhosis
10.3969/j.issn.1674-7445.2020.01.013
- VernacularTitle:自身免疫性肝病与病毒性肝炎肝硬化肝移植预后差异配对分析
- Author:
Zhanyu SONG
1
;
Qi PAN
;
Yang YU
;
Degong JIA
;
Yongfeng LIU
Author Information
1. Department of Organ Transplantation, Hepatobiliary Surgery, the First Affiliated Hospital of China Medical University, Shenyang 110000, China
- Publication Type:Research Article
- Keywords:
Autoimmune liver disease;
Primary biliary cholangitis;
Primary sclerosing cholangitis;
Autoimmune hepatitis;
Viral hepatitis cirrhosis;
Liver transplantation;
Prognosis
- From:
Organ Transplantation
2020;11(1):82-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the difference and influential factors of clinical prognosis between liver transplantation with autoimmune liver disease (AILD) and viral hepatitis cirrhosis. Methods Clinical data of 75 recipients undergoing liver transplantation from January 2002 to January 2017 were retrospectively analyzed. All recipients were divided into the AILD group (n=25) and viral hepatitis cirrhosis group (n=50). The intraoperative conditions of the recipients were observed including warm ischemia time, cold ischemia time, operation time, anhepatic phase and blood transfusion volume. Postoperative complications were observed including severe acute kidney injury (AKI), infection, acute rejection, biliary tract-related complications, vascular-related complications and post transplantation diabetes mellitus (PTDM). The follow-up status were monitored after discharge. The prognostic factors of liver transplant recipients were analyzed. Results The warm ischemia time, cold ischemia time, operation time and anhepatic phase did not significantly differ between two groups (all P > 0.05). In the AILD group, the incidence of postoperative acute rejection was remarkably higher, whereas the incidence of postoperative severe AKI was significantly lower than those in the viral hepatitis cirrhosis group (both P < 0.05). The postoperative 1-, 3- and 5-year survival rates in the AILD group was 92%, 87%, and 87%, which did not significantly differ from 88%, 88% and 88% in the viral hepatitis cirrhosis group (all P > 0.05). Univariate analysis showed that age, model for end-stage liver disease (MELD) score, severe AKI, infection and biliary tract-related complications were the influencing factors of clinical prognosis of the recipients (all P < 0.05). Conclusions The overall survival prognosis does not significantly differ between the AILD and viral hepatitis cirrhosis groups. Age, MELD score, severe AKI, infection and biliary tract-related complications are the risk factors affecting the clinical prognosis of liver transplantation recipients.
